Related Experiment Video
Updated: Jul 31, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Targeting DNA damage repair precision medicine strategies in cancer
Juliette Brownlie1, Sanat Kulkarni2, Mashael Algethami1
1Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Abstract:
DNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with BRCA germline deficient breast and ovarian cancer as well as platinum sensitive epithelial ovarian cancers. However, lessons learnt from the clinical use of PARP inhibitors also confirm that not all patients respond either due to intrinsic or acquired resistance. Therefore, the search for additional synthetic lethality approaches is an active area of translational and clinical research. Here, we review the current clinical state of PARP inhibitors and other evolving DNA repair targets including ATM, ATR, WEE1 inhibitors and others in cancer.
Insights
PARP inhibitors offer precision medicine for BRCA-deficient cancers, but resistance necessitates new DNA repair targeted therapies. Research is exploring additional synthetic lethality strategies for improved cancer treatment.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- DNA repair mechanisms are crucial for cancer cell survival.
- Targeting DNA repair pathways represents a promising precision medicine strategy.
- Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in specific cancer types.
Purpose of the Study:
- To review the clinical status of PARP inhibitors in cancer treatment.
- To discuss emerging DNA repair targeted therapeutics.
- To highlight the ongoing search for novel synthetic lethality approaches.
Main Methods:
- Literature review of clinical trials and translational research.
- Analysis of the clinical utility and resistance mechanisms of PARP inhibitors.
- Overview of other DNA repair targets in clinical development.
Main Results:
- PARP inhibitors have transformed treatment for BRCA-mutated breast and ovarian cancers.
- Intrinsic and acquired resistance limits PARP inhibitor effectiveness in some patients.
- ATM, ATR, and WEE1 inhibitors are among other DNA repair targets under investigation.
Conclusions:
- While PARP inhibitors are effective, overcoming resistance is key.
- Expanding the scope of DNA repair targeted therapies is essential for broader patient benefit.
- Continued research into synthetic lethality holds promise for future cancer treatments.
More Related Videos
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
DNA Damage can Stall the Cell Cycle
Overview of DNA Repair
Chemically...
Long-patch Base Excision Repair
Base Excision Repair
The first step of...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

